Rinvoq
Third positive trial sets up filings for AbbVie’s Rinvoq in Crohn’s
Phil Taylor
AbbVie, Crohn's disease, inflammatory bowel disease, Rinvoq
0 Comment
News/ News/ Sales and Marketing
Leo puts target on Dupixent in US as FDA clears tralokinumab
Phil Taylor
AbbVie, atopic dermatitis, Cibinqo, dermatology, Eli Lilly, lebrikizumab, LEO Pharma, Olumiant, Pfizer, Regeneron, regulatory approval, Rinvoq, Sanofi, tralokinumab
0 Comment
FDA firms up JAK inhibitor warnings after Xeljanz review
Phil Taylor
AbbVie, Eli Lilly, fda, JAK inhibitor, Olumiant, Pfizer, Rheumatoid arthritis, Rinvoq, safety, Xeljanz
0 Comment
AbbVie’s Rinvoq cleared in EU for atopic dermatitis
Phil Taylor
AbbVie, atopic dermatitis, EU, JAK inhibitor, regulatory approval, Rinvoq
0 Comment
News/ News/ Sales and Marketing
FDA holds back from action over Xeljanz safety study
Phil Taylor
AbbVie, fda, JAK inhibitor, Pfizer, Rheumatoid arthritis, Rinvoq, safety, side effects, Xeljanz
0 Comment
News/ News/ Sales and Marketing
Bad news for Pfizer as blockbuster Xeljanz flunks safety study
Phil Taylor
AbbVie, Pfizer, Rinvoq, safety, Xeljanz
0 Comment